Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2012

01-02-2012 | Special Topic

Molecular Imaging and Contrast Agent Database (MICAD): Evolution and Progress

Authors: Arvind Chopra, Liang Shan, W. C. Eckelman, Kam Leung, Martin Latterner, Stephen H. Bryant, Anne Menkens

Published in: Molecular Imaging and Biology | Issue 1/2012

Login to get access

Abstract

The purpose of writing this review is to showcase the Molecular Imaging and Contrast Agent Database (MICAD; www.​micad.​nlm.​nih.​gov) to students, researchers, and clinical investigators interested in the different aspects of molecular imaging. This database provides freely accessible, current, online scientific information regarding molecular imaging (MI) probes and contrast agents (CA) used for positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, X-ray/computed tomography, optical imaging and ultrasound imaging. Detailed information on >1,000 agents in MICAD is provided in a chapter format and can be accessed through PubMed. Lists containing >4,250 unique MI probes and CAs published in peer-reviewed journals and agents approved by the United States Food and Drug Administration as well as a comma separated values file summarizing all chapters in the database can be downloaded from the MICAD homepage. Users can search for agents in MICAD on the basis of imaging modality, source of signal/contrast, agent or target category, pre-clinical or clinical studies, and text words. Chapters in MICAD describe the chemical characteristics (structures linked to PubChem), the in vitro and in vivo activities, and other relevant information regarding an imaging agent. All references in the chapters have links to PubMed. A Supplemental Information Section in each chapter is available to share unpublished information regarding an agent. A Guest Author Program is available to facilitate rapid expansion of the database. Members of the imaging community registered with MICAD periodically receive an e-mail announcement (eAnnouncement) that lists new chapters uploaded to the database. Users of MICAD are encouraged to provide feedback, comments, or suggestions for further improvement of the database by writing to the editors at micad@nlm.nih.gov.
Literature
1.
Cheng KT, Menkens A, Bryant S et al (2007) NIH MICAD initiative and guest author program opportunities. J Nucl Med 48:19NPubMedCrossRef
2.
Chopra A, Shan L, Eckelman EC, et al. (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol [Epub ahead of print].
3.
Willmann JK, van Bruggen N, Dinkelborg LM et al (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591–607PubMedCrossRef
4.
Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580PubMedCrossRef
5.
6.
Amidon GL (2004) Molecular pharmaceutics: the NIH Roadmap and the FDA pipeline problem. Mol Pharm 1:337PubMedCrossRef
7.
8.
Shi ZD, Wu H, Ruddy B et al (2007) Imaging Probe Development Center: a National Institutes of Health core synthesis resource for imaging probes. J Biomed Opt 12:051502PubMedCrossRef
9.
Sayers EW, Barrett T, Benson DA et al (2011) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 39:D38–D51PubMedCrossRef
10.
Haight AE, Kaste SC, Goloubeva OG et al (2003) Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation. Radiology 226:399–404PubMedCrossRef
11.
Weichert JP, Lee FT Jr, Longino MA et al (1998) Lipid-based blood-pool CT imaging of the liver. Acad Radiol 5(Suppl 1):S16–S19, discussion S28-30PubMedCrossRef
12.
Ford NL, Graham KC, Groom AC et al (2006) Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest Radiol 41:384–390PubMedCrossRef
13.
Cheong BY, Muthupillai R (2010) Nephrogenic systemic fibrosis: a concise review for cardiologists. Tex Heart Inst J 37:508–515PubMed
14.
Cho EC, Glaus C, Chen J et al (2010) Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med 16:561–573PubMedCrossRef
15.
Godin B, Driessen WH, Proneth B et al (2010) An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet 69:31–64PubMedCrossRef
16.
17.
Hasebroock KM, Serkova NJ (2009) Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 5:403–416PubMedCrossRef
18.
Hallouard F, Anton N, Choquet P et al (2010) Iodinated blood pool contrast media for preclinical X-ray imaging applications—a review. Biomaterials 31:6249–6268PubMedCrossRef
19.
Kozlowska D, Foran P, MacMahon P et al (2009) Molecular and magnetic resonance imaging: the value of immunoliposomes. Adv Drug Deliv Rev 61:1402–1411PubMedCrossRef
20.
Sheth RA, Mahmood U (2010) Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 299:G807–G820PubMedCrossRef
21.
Longmire MR, Ogawa M, Hama Y et al (2008) Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem 19:1735–1742PubMedCrossRef
22.
Eckelman WC, Kilbourn MR, Joyal JL et al (2007) Justifying the number of animals for each experiment. Nucl Med Biol 34:229–232PubMedCrossRef
23.
Boerman OC, Rennen H, Oyen WJ et al (2001) Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 31:286–295PubMedCrossRef
24.
Chen JH, Baek HM, Nalcioglu O et al (2008) Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 27:825–833PubMedCrossRef
25.
Roelofs AJ, Thompson K, Gordon S et al (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s–6230sPubMedCrossRef
26.
Mukherjee S, Mani S (2010) Orphan nuclear receptors as targets for drug development. Pharm Res 27:1439–1468PubMedCrossRef
27.
Ozawa A, Lindberg I, Roth B et al (2010) Deorphanization of novel peptides and their receptors. AAPS J 12:378–384PubMedCrossRef
Metadata
Title
Molecular Imaging and Contrast Agent Database (MICAD): Evolution and Progress
Authors
Arvind Chopra
Liang Shan
W. C. Eckelman
Kam Leung
Martin Latterner
Stephen H. Bryant
Anne Menkens
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 1/2012
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-011-0521-3

Other articles of this Issue 1/2012

Molecular Imaging and Biology 1/2012 Go to the issue

Brief Article

Targeted Multifunctional Multimodal Protein-Shell Microspheres as Cancer Imaging Contrast Agents

Research Article

Human Biodistribution and Dosimetry of the PET Radioligand [11C]Flumazenil (FMZ)

Research Article

Value of FDG PET/CT in Patients with Treated Ovarian Cancer and Raised CA125 Serum Levels

Research Article

The Effect of Inhaled Gases on Ultrasound Contrast Agent Longevity In Vivo

Research Article

Positron Emission Tomography Imaging of Tumors Expressing the Human Chemokine Receptor CXCR4 in Mice with the Use of 64Cu-AMD3100

Editorial

The World Molecular Imaging Society (WMIS)